查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088847

神經生物標記市場：2026-2032年全球市場預測（按生物標記類型、技術平台、檢體來源、應用和最終用戶分類）

Neurological Biomarkers Market by Biomarker Type, Technology Platform, Specimen Source, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，神經生物標記市場將成長至 217.4 億美元，複合年成長率為 13.90%。

主要市場統計數據
基準年 2025 87.4億美元
預計年份：2026年 98.8億美元
預測年份 2032 217.4億美元
複合年成長率 (%) 13.90%

神經生物標記是能夠測量生物學特徵、治療反應或疾病風險的指標，例如阿茲海默症、帕金森氏症、多發性硬化症、癲癇、創傷性腦損傷、中風和罕見的神經退化性疾病。該領域已從專門的神經影像學和腦脊髓液檢測發展到涵蓋多種血液生物標記、數位生物標記、神經生理學、基因組學、蛋白質組學、代謝體學和人工智慧驅動的圖像分析。

全球神經系統疾病負擔的加重進一步加劇了這項需求。世界衛生組織（世衛組織）在2024年報告中指出，全球有超過30億人患有神經系統疾病，其中失智症患者超過5500萬，癲癇患者約5000萬。這些流行病學壓力正促使神經系統生物標記從單純的調查工具轉變為早期診斷、患者分層、最佳化臨床試驗參與者選擇以及監測疾病進展的關鍵基礎設施。

當檢驗的生物標記能夠降低診斷不確定性、縮短臨床開發週期並支持精準神經科學時，其應用前景最為廣闊。血液來源的阿茲海默症標記、指示神經軸突損傷的神經絲輕鏈、PET、先進的MRI、基於腦電圖的指標以及運動和認知Tau的數位化測量，正日益成為臨床和商業策略的核心。

神經生物標記領域的變革性變化

神經生物標記領域正經歷三大結構性變革：從終末期診斷轉向早期風險檢測；從單一模式檢測轉向多體學和多模態數據整合；以及從研究性檢測轉向臨床應用型診斷方法。這些變革的驅動力在於，需要在不可逆的神經退化發生之前檢測出疾病的生物學機制，並為患者匹配合適的標靶治療。

人工智慧對神經生物標記的累積影響

人工智慧 (AI) 透過改善醫學影像、電生理、語音、步態、認知和穿戴式感測器數據中的模式識別，加速了神經生物標記的發現和實用化。 AI 模型有助於識別 MRI、PET、視網膜成像、腦電圖 (EEG) 和數位行為資料流中難以透過傳統臨床評估檢測到的細微變化。

神經生物標記方面的關鍵區域性見解

北美憑藉其強大的學術醫療中心、活躍的臨床試驗基礎設施、完善的監管流程以及先進的神經影像學和分子診斷技術的應用，仍然是神經生物標記創新領域的主導地區。美國正透過與美國食品藥物管理局（FDA）的合作、為保險公司提供證據以及建立專家神經病學網路來推動商業化進程，而加拿大則透過其神經科學研究計畫、公共衛生數據資產和人群層面的研究基礎設施做出貢獻。

針對東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵群體特定見解

在東協地區，人口成長、私人醫療保健的擴張以及對失智症、中風、癲癇和神經發育障礙日益成長的關注，正在推動對神經生物標記的需求。然而，各成員國獲得正子斷層掃描（PET）影像、先進磁振造影（MRI）和專業檢查室的機會仍不均衡。海灣合作理事會（GCC）國家正在投資三級醫療、精準醫療、基因組學和數位健康基礎設施，為都市區醫療系統和專科醫療中心的高價值神經系統診斷創造有利環境。

關於引入神經生物標記的關鍵國家特定見解

美國在商業化、與FDA的合作、臨床試驗活動、先進影像技術、檢查室自建檢測以及保險公司主導的證據要求方面發揮主導作用。另一方面，加拿大在神經科學研究和公共衛生數據方面擁有強大的實力。墨西哥和巴西是拉丁美洲的重要市場，其專科醫療、學術研究和臨床試驗活動都在不斷發展，但同時也面臨成本效益、保險報銷和醫療服務可近性方面的挑戰。

為神經生物標記領域的領導者提供的實用建議

產業領導者應優先考慮那些不僅具備分析能力，而且具有明確臨床效用的生物標記。最具發展潛力的檢測方法包括：指導治療方案選擇、確診疾病病理、識別疾病進展風險、減少臨床試驗中的篩檢失敗，以及在真實神經系統疾病診療環境中監測治療反應。

調查方法

本執行摘要採用二手研究架構編寫，重點檢驗的公共資訊來源、同行評審的科學文獻、監管資訊、疾病負擔數據和醫療基礎設施指標。主要參考類別包括世界衛生組織神經系統疾病統計數據、美國食品藥物管理局醫療設備和診斷資訊、歐洲藥品管理局和歐盟法規結構、各國衛生機構、臨床試驗註冊資訊以及已發布的臨床共識聲明。

結論

隨著醫療系統致力於早期診斷、更精準的患者分層和對複雜腦部疾病的客觀監測，神經生物標記正成為精準神經科學的基石。血液檢測、先進影像技術、數位化測量、神經生理學、多組體學和人工智慧的融合，正推動神經生物標記的應用範圍從研究和臨床試驗擴展到常規臨床流程。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 神經生物標記市場：依生物標記類型分類

  • 蛋白質生物標記
    • Tau蛋白
    • 乙型澱粉樣蛋白
    • 神經絲輕鏈
    • α-突觸核蛋白
  • 基因生物標記
    • APOE基因型
    • 突變
    • 拷貝編號變體
    • 微衛星標記
  • 蛋白質體學生物標記
  • 代謝生物標記
  • 代謝體學物標誌物
  • 氧化壓力生物標記

第8章 神經生物標記市場：依技術平台分類

  • 酵素免疫分析法（ELISA）
  • 影像技術
    • 電腦斷層掃描（CT）
    • 功能性近紅外線光譜
    • 磁振造影（MRI）
    • 正子斷層掃描（PET）
  • 質譜分析
  • 次世代定序
    • RNA定序
    • 標靶重測序
    • 全基因測序
  • 聚合酵素鏈鎖反應

第9章 神經生物標記市場：依檢體來源分類

  • 腦脊髓液
  • 血液衍生的
    • 血清
    • 電漿
    • 全血
    • 乾血斑
  • 尿
  • 唾液

第10章 神經生物標記市場：依應用領域分類

  • 診斷
  • 藥物研發
  • 監測
  • 預後
  • 調查

第11章 神經生物標記市場：依最終用戶分類

  • 受託研究機構
  • 診斷檢查室
  • 醫院和診所
  • 製藥和生物技術公司
  • 研究機構

第12章 神經生物標記市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 神經生物標記市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 神經生物標記市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Acumen Pharmaceuticals Inc.
  • ADx NeuroSciences NV
  • Agilent Technologies, Inc.
  • Alector Inc.
  • Altoida Inc.
  • Banyan Biomarkers, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biogen Inc.
  • bioMerieux SA
  • Bruker Corporation
  • C2N Diagnostics, LLC
  • Charles River Laboratories International, Inc.
  • CND Life Sciences
  • Danaher Corporation
  • Eli Lilly and Company
  • Euroimmun AG
  • F. Hoffmann-La Roche AG
  • GE HealthCare Technologies Inc.
  • Illumina, Inc.
  • Invicro LLC
  • Johnson & Johnson Services, Inc.
  • Laboratory Corporation of America Holdings
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Qiagen NV
  • Quanterix Corporation
  • Siemens Healthineers AG
Product Code: MRR-AD36CD897EE7

The Neurological Biomarkers Market is projected to grow by USD 21.74 billion at a CAGR of 13.90% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.74 billion
Estimated Year [2026] USD 9.88 billion
Forecast Year [2032] USD 21.74 billion
CAGR (%) 13.90%

Neurological biomarkers are measurable indicators of disease biology, treatment response, or risk across conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, traumatic brain injury, stroke, and rare neurodegenerative disorders. The field is moving beyond specialist neuroimaging and cerebrospinal fluid testing toward scalable blood-based biomarkers, digital biomarkers, neurophysiology, genomics, proteomics, metabolomics, and AI-enabled image analytics.

Demand is reinforced by the global burden of neurological disease. The World Health Organization reported in 2024 that neurological conditions affect more than 3 billion people worldwide, while dementia affects more than 55 million people and epilepsy affects around 50 million. These epidemiological pressures are elevating neurological biomarkers from research tools to essential infrastructure for earlier diagnosis, patient stratification, clinical trial enrichment, and monitoring of disease progression.

The opportunity is strongest where validated biomarkers reduce diagnostic uncertainty, shorten clinical development timelines, and support precision neurology. Blood-based Alzheimer's biomarkers, neurofilament light chain for neuroaxonal injury, amyloid and tau PET, advanced MRI, EEG-based indicators, and digital motor and cognitive measures are becoming central to clinical and commercial strategies.

Transformative Shifts in the Neurological Biomarkers Landscape

The neurological biomarkers landscape is being reshaped by three structural shifts: the move from late-stage diagnosis to earlier risk detection, the shift from single-modality testing to multi-omics and multimodal data integration, and the transition from research-grade assays to clinically deployable diagnostics. These shifts are driven by the need to detect disease biology before irreversible neurodegeneration and to match patients with targeted therapies.

Alzheimer's disease is a leading example. Disease-modifying therapies that require confirmation of amyloid pathology have increased the need for PET, CSF, and emerging plasma biomarkers, while also strengthening demand for objective monitoring of safety and treatment response. In multiple sclerosis and traumatic brain injury, neurofilament light chain is gaining traction as a marker of neuronal injury, while digital biomarkers are expanding continuous assessment beyond episodic clinic visits.

Commercial differentiation is increasingly tied to analytical validity, clinical validity, clinical utility, regulatory readiness, payer evidence, and interoperability with electronic health records and decentralized trial platforms. Organizations that combine biomarker performance with workflow integration are better positioned than those offering isolated assays.

Cumulative Impact of Artificial Intelligence on Neurological Biomarkers

Artificial intelligence is accelerating neurological biomarker discovery and deployment by improving pattern recognition in imaging, electrophysiology, speech, gait, cognition, and wearable sensor data. AI models can help identify subtle changes in MRI, PET, retinal imaging, EEG, and digital behavior streams that may be difficult to detect through conventional clinical review.

The regulatory environment is also maturing. The U.S. FDA's public inventory of AI/ML-enabled medical devices had surpassed 950 authorized devices by 2024, with radiology representing the largest category, indicating broad acceptance of AI-assisted interpretation when supported by evidence. In neurology, AI is most valuable when it enhances reproducibility, reduces reader variability, improves triage, and supports longitudinal measurement.

The cumulative impact is a shift from biomarker measurement to biomarker intelligence. However, leaders must manage model bias, data provenance, cybersecurity, explainability, and post-market performance monitoring. AI-enabled neurological biomarkers will gain trust fastest when trained on diverse datasets and validated prospectively across populations, devices, and care settings.

Key Regional Insights for Neurological Biomarkers

North America remains a leading region for neurological biomarker innovation due to strong academic medical centers, active clinical trial infrastructure, established regulatory pathways, and adoption of advanced neuroimaging and molecular diagnostics. The United States anchors commercialization through FDA engagement, payer evidence development, and specialty neurology networks, while Canada contributes through neuroscience research programs, public health data assets, and population-level research infrastructure.

Europe is characterized by coordinated research, biobanks, and regulatory rigor under frameworks such as the In Vitro Diagnostic Regulation and General Data Protection Regulation. The European Union's emphasis on health data governance supports high-quality evidence generation, while the United Kingdom, Germany, France, Italy, and Spain remain important centers for clinical research, diagnostics adoption, dementia programs, and neurodegenerative disease studies.

Asia-Pacific is expanding as China, Japan, India, South Korea, and Australia invest in neuroscience, genomics, AI health technologies, and aging-related care. Latin America, led by Brazil and Mexico, shows rising demand for neurological diagnostics but continues to face access, reimbursement, and specialist availability constraints. The Middle East, especially GCC healthcare hubs, is building tertiary neurology, precision medicine, and digital health capacity, while Africa presents long-term potential through improved diagnostics, research partnerships, workforce development, and scalable point-of-care approaches.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

Within ASEAN, demand for neurological biomarkers is shaped by population growth, expanding private healthcare, and increasing attention to dementia, stroke, epilepsy, and neurodevelopmental disorders, although access to PET imaging, advanced MRI, and specialized laboratories remains uneven across member states. The GCC is investing in tertiary care, precision medicine, genomic initiatives, and digital health infrastructure, creating a favorable environment for high-value neurological diagnostics in urban health systems and specialist centers.

The European Union offers one of the most structured environments for biomarker evidence generation, supported by multicountry research programs, biobanks, harmonized regulatory expectations, and strong data protection requirements. BRICS economies combine high disease burden with expanding diagnostic capacity, making affordability, local clinical validation, workforce development, and scalable blood-based assays critical to broader adoption.

G7 markets represent the strongest concentration of reimbursement systems, pharmaceutical R&D, advanced imaging infrastructure, and specialty neurology capacity, supporting faster translation of validated neurological biomarkers into clinical and trial workflows. NATO countries overlap significantly with high-income markets where traumatic brain injury research, veteran brain health, secure health data systems, and resilient medical infrastructure can influence biomarker deployment.

Key Country Insights for Neurological Biomarker Adoption

The United States leads in commercialization, FDA interactions, clinical trial activity, advanced imaging, laboratory-developed testing, and payer-driven evidence requirements, while Canada provides strong neuroscience research and public health data capabilities. Mexico and Brazil are important Latin American markets where growing specialty care, academic research, and clinical trial activity coexist with affordability, reimbursement, and access challenges.

In Europe, the United Kingdom, Germany, and France are central to biomarker research, diagnostics adoption, dementia initiatives, and pharmaceutical partnerships. Italy and Spain contribute through strong neurology networks, aging populations, and clinical trial participation, while Russia has scientific and clinical capacity but faces geopolitical, regulatory, and market access constraints.

In Asia-Pacific, China is scaling biotechnology, AI, genomics, and diagnostics infrastructure; India offers a large patient population and expanding laboratory networks; Japan has a high aging burden and advanced medical technology adoption; Australia supports high-quality clinical research and neurodegenerative disease programs; and South Korea is a strong digital health, imaging, and medtech innovation hub.

Actionable Recommendations for Neurological Biomarker Leaders

Industry leaders should prioritize biomarkers with clear clinical utility, not only analytical performance. The strongest opportunities are in tests that guide therapy selection, confirm disease pathology, identify progression risk, reduce clinical trial screen failures, or monitor treatment response in real-world neurology settings.

Organizations should build evidence packages that include diverse cohorts, longitudinal outcomes, health economic value, and real-world performance. Partnerships with academic centers, biobanks, clinical trial networks, imaging providers, pharmaceutical sponsors, and digital health platforms can accelerate validation, regulatory readiness, and adoption.

Executives should also invest in regulatory strategy, data governance, interoperability, cybersecurity, and payer engagement early. Scalable blood-based assays, AI-enabled imaging workflows, and digital biomarkers should be designed for integration into neurology clinics, memory centers, emergency care, decentralized trials, and remote monitoring programs.

Research Methodology

This executive summary is developed using a secondary research framework focused on verified public sources, peer-reviewed scientific literature, regulatory information, disease burden data, and healthcare infrastructure indicators. Key reference categories include WHO neurological disease statistics, FDA device and diagnostic information, EMA and EU regulatory frameworks, national health agencies, clinical trial registries, and published clinical consensus statements.

The analysis evaluates biomarker modalities including blood, CSF, neuroimaging, electrophysiology, digital biomarkers, genetics, proteomics, and metabolomics. Interpretation emphasizes clinical adoption, regulatory readiness, reimbursement potential, competitive differentiation, regional healthcare capacity, and evidence requirements for precision neurology.

Insights are synthesized to support executive decision-making without presenting unverified market sizing, market share, or forecasts. Where numeric data are included, they reflect publicly reported disease burden or regulatory indicators from recognized sources.

Conclusion

Neurological biomarkers are becoming foundational to precision neurology as healthcare systems seek earlier diagnosis, better patient stratification, and objective monitoring of complex brain disorders. The convergence of blood-based testing, advanced imaging, digital measures, neurophysiology, multi-omics, and artificial intelligence is expanding use cases from research and clinical trials into routine care pathways.

The next phase of adoption will depend on validation, equity, reimbursement, regulatory confidence, and trust. Organizations that combine scientific rigor with scalable deployment, strong data governance, workflow integration, and payer-relevant evidence will be best positioned to lead in the neurological biomarkers landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neurological Biomarkers Market, by Biomarker Type

  • 7.1. Protein Biomarkers
    • 7.1.1. Tau Proteins
    • 7.1.2. Amyloid-Beta
    • 7.1.3. Neurofilament Light Chain
    • 7.1.4. Alpha-Synuclein
  • 7.2. Genetic Biomarkers
    • 7.2.1. APOE Genotype
    • 7.2.2. Mutations
    • 7.2.3. Copy Number Variations
    • 7.2.4. Microsatellite Markers
  • 7.3. Proteomic Biomarkers
  • 7.4. Metabolic Biomarkers
  • 7.5. Metabolomic Biomarkers
  • 7.6. Oxidative Stress Biomarkers

8. Neurological Biomarkers Market, by Technology Platform

  • 8.1. Enzyme-Linked Immunosorbent Assay
  • 8.2. Imaging Techniques
    • 8.2.1. Computed Tomography
    • 8.2.2. Functional Near-Infrared Spectroscopy
    • 8.2.3. Magnetic Resonance Imaging
    • 8.2.4. Positron Emission Tomography
  • 8.3. Mass Spectrometry
  • 8.4. Next-Generation Sequencing
    • 8.4.1. RNA Sequencing
    • 8.4.2. Targeted Resequencing
    • 8.4.3. Whole Genome Sequencing
  • 8.5. Polymerase Chain Reaction

9. Neurological Biomarkers Market, by Specimen Source

  • 9.1. Cerebrospinal Fluid
  • 9.2. Blood-Based
    • 9.2.1. Serum
    • 9.2.2. Plasma
    • 9.2.3. Whole Blood
    • 9.2.4. Dried Blood Spots
  • 9.3. Urine
  • 9.4. Saliva

10. Neurological Biomarkers Market, by Application

  • 10.1. Diagnostics
  • 10.2. Drug Development
  • 10.3. Monitoring
  • 10.4. Prognostics
  • 10.5. Research

11. Neurological Biomarkers Market, by End User

  • 11.1. Contract Research Organizations
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals & Clinics
  • 11.4. Pharmaceutical & Biotechnology Companies
  • 11.5. Research Institutes

12. Neurological Biomarkers Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Neurological Biomarkers Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neurological Biomarkers Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Acumen Pharmaceuticals Inc.
  • 16.3. ADx NeuroSciences NV
  • 16.4. Agilent Technologies, Inc.
  • 16.5. Alector Inc.
  • 16.6. Altoida Inc.
  • 16.7. Banyan Biomarkers, Inc.
  • 16.8. Becton, Dickinson and Company
  • 16.9. Bio-Rad Laboratories, Inc.
  • 16.10. Bio-Techne Corporation
  • 16.11. Biogen Inc.
  • 16.12. bioMerieux SA
  • 16.13. Bruker Corporation
  • 16.14. C2N Diagnostics, LLC
  • 16.15. Charles River Laboratories International, Inc.
  • 16.16. CND Life Sciences
  • 16.17. Danaher Corporation
  • 16.18. Eli Lilly and Company
  • 16.19. Euroimmun AG
  • 16.20. F. Hoffmann-La Roche AG
  • 16.21. GE HealthCare Technologies Inc.
  • 16.22. Illumina, Inc.
  • 16.23. Invicro LLC
  • 16.24. Johnson & Johnson Services, Inc.
  • 16.25. Laboratory Corporation of America Holdings
  • 16.26. Merck KGaA
  • 16.27. Myriad Genetics, Inc.
  • 16.28. Qiagen N.V.
  • 16.29. Quanterix Corporation
  • 16.30. Siemens Healthineers AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROLOGICAL BIOMARKERS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NEUROLOGICAL BIOMARKERS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NEUROLOGICAL BIOMARKERS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PROTEIN BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PROTEIN BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROTEIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TAU PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TAU PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TAU PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AMYLOID-BETA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AMYLOID-BETA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AMYLOID-BETA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROFILAMENT LIGHT CHAIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROFILAMENT LIGHT CHAIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROFILAMENT LIGHT CHAIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALPHA-SYNUCLEIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ALPHA-SYNUCLEIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ALPHA-SYNUCLEIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENETIC BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENETIC BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENETIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL APOE GENOTYPE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL APOE GENOTYPE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL APOE GENOTYPE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MUTATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MUTATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MUTATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COPY NUMBER VARIATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COPY NUMBER VARIATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COPY NUMBER VARIATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MICROSATELLITE MARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MICROSATELLITE MARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MICROSATELLITE MARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROTEOMIC BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PROTEOMIC BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROTEOMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL METABOLIC BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL METABOLIC BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL METABOLIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL METABOLOMIC BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL METABOLOMIC BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL METABOLOMIC BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OXIDATIVE STRESS BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OXIDATIVE STRESS BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OXIDATIVE STRESS BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENZYME-LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMAGING TECHNIQUES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMAGING TECHNIQUES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMAGING TECHNIQUES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPUTED TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FUNCTIONAL NEAR-INFRARED SPECTROSCOPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FUNCTIONAL NEAR-INFRARED SPECTROSCOPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FUNCTIONAL NEAR-INFRARED SPECTROSCOPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MAGNETIC RESONANCE IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MASS SPECTROMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RNA SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RNA SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RNA SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TARGETED RESEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TARGETED RESEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TARGETED RESEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CEREBROSPINAL FLUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BLOOD-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOOD-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BLOOD-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL WHOLE BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL WHOLE BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL WHOLE BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DRIED BLOOD SPOTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRIED BLOOD SPOTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DRIED BLOOD SPOTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SALIVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DRUG DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DRUG DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PROGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PROGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PROGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 219. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 221. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 222. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 223. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 224. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 225. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 226. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 227. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. GCC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 254. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 255. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 256. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 257. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 258. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 259. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 260. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. G7 NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 265. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 266. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 267. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 268. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 269. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 270. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 271. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 272. NATO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 288. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 289. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 290. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 291. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 292. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 293. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 294. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 295. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 296. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 299. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 300. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 301. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 302. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 303. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 304. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 305. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 306. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 310. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 311. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 312. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 313. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 314. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 315. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 316. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 317. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 329. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 330. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 332. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 333. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 334. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 335. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 336. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 337. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 338. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 339. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 340. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 341. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 343. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENETIC BIOMARKERS, 2018-2032 (USD MILLION)
  • TABLE 344. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 345. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING TECHNIQUES, 2018-2032 (USD MILLION)
  • TABLE 346. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 347. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY SPECIMEN SOURCE, 2018-2032 (USD MILLION)
  • TABLE 348. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY BLOOD-BASED, 2018-2032 (USD MILLION)
  • TABLE 349. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION